Stock AST ASTERIAS BIOTHERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up

News Asterias Biotherapeutics Inc

Equities

AST

US04624N1072

Delayed Nyse
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Asterias Biotherapeutics Inc +3.85% +52.42%

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
GL
Asterias Biotherapeutics Reports Third Quarter Results
GL
Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
BU
Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
BU
Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
GL
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
GL
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
GL
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
GL
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
GL
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
GL
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
GL
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
GL
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
GL
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
GL
Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
GL
Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
GL
Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
GL
Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting                                                            
GL
Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference
GL
Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AST Stock
  4. News Asterias Biotherapeutics Inc